Operator

Good afternoon, and welcome to the Eton Pharmaceuticals First Quarter 2026 Financial Results Conference Call. [Operator Instructions] Please be advised that this call is being recorded at the company's request.

At this time, I'd like to turn it over to David Krempa, Chief Business Officer at Eton Pharmaceuticals. Please proceed.

David Krempa
Chief Business Officer

Thank you, operator. Good afternoon, everyone, and welcome to Eton's First Quarter 2026 Conference Call. This afternoon, we issued a press release that outlines the topics we plan to discuss on today's call. The release is available on our website, etonpharma.com.

Joining me on our call today, we have Sean Brynjelsen, our CEO; James Gruber, our CFO; Judy Matthews, our Executive Vice President of Finance; and Ipek Trinkaus, our Chief Commercial Officer.

In addition to taking live questions on today's call, we will also be answering questions that are e-mailed to us. Investors can send their questions to Investor Relations at etonpharma.com.

Before we begin, I would like to remind everyone that remarks made during the call may contain forward-looking statements that involve risks and uncertainties that could cause the actual results to differ materially from those contained in these forward-looking statements. Please see the forward-looking statements disclaimer in our earnings release and the risk factors in the company's filings with the SEC.

Now I will turn the call over to our